Responseevaluation durch Positronenemissionstomographie (PET) im Rahmen der neoadjuvanten Therapie

Translated title of the contribution: Monitoring of response to neoadjuvant therapy by positron emission tomography

K. Ott, W. A. Weber, U. Fink, M. Schwaiger, J. R. Siewert

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Neoadjuvant therapy is frequently hampered by the lack of reliable non-invasive techniques for prediction and assessment of response. Positron emission tomography using the glucose analogue 18F-fluorodeoxyglucose (FDG-PET) provides a unique means of non-invasive assessment of tumor metabolism. Several recent studies have indicated that a reduction of tumor metabolic activity after neoadjuvant therapy is closely correlated with the degree of histopathological tumor regression. The reduction of metabolic activity may also allow one to predict subsequent response early during the course of therapy. Therefore FDG-PET may permit individualized therapy management. However, there is a requirement for larger-scale trials to assess this technique.

Translated title of the contributionMonitoring of response to neoadjuvant therapy by positron emission tomography
Original languageGerman
Pages (from-to)1003-1009
Number of pages7
JournalChirurg
Volume72
Issue number9
DOIs
StatePublished - Sep 2001
Externally publishedYes

Fingerprint

Dive into the research topics of 'Monitoring of response to neoadjuvant therapy by positron emission tomography'. Together they form a unique fingerprint.

Cite this